Source: Pharmaceutical Technology
Incannex’s CEO Joel Latham announced an upcoming IND submission. Credit: SOPA Images via Getty Images Free ReportHow is the Biopharmaceutical industry evolving?
2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.
Benchmark the impact of major themes on the Biopharmaceutical industry.
Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success.
Source: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
-->By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Submit
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Thank you.You will receive an email shortly. Please check for download the Report.
Go deeper with GlobalData
Source: Pharmaceutical Technology
Source: Pharmaceutical Technology
The gold standard of business intelligence.
Related Company ProfilesNasdaq IncView all
“We have been working with the Medicines and Healthcare Products Regulatory Agency (MHRA) and various clinical trial sites in the UK,” said Latham in an exclusive interview with Pharmaceutical Technology. The company is working through onboarding and commencing the site in the UK first and in parallel working with the US Food and Drug Administration (FDA) to open an IND, says Latham. He explains that the trial will be a multi-site, multi-jurisdictional pivotal Phase IIb study. The Sydney, Australia-based company is currently finalising stability data from its manufacturing processes to include in the IND filing. Psi-GAD is a psilocybin therapy that treats generalised anxiety disorder by modulating the serotonin system for mood regulation. On 28 February, Incannex released interim data from the initial Phase II Psi-GAD-1 clinical study (ACTRN12621001358831), announcing that the therapy had significantly achieved improvements in the primary endpoint of the Hamilton Anxiety Rating Scale (HAM-A). In terms of financing, the CEO says that the biotech is in a secure position, partially due to its support from the Australian government. Despite being a Nasdaq-listed company, Incannex runs the majority of its operations in Australia, allowing it to take advantage of the country’s R&D tax rebates. Latham says that for all its R&D spend in Australia, the government offsets 43.5% of the taxation. This benefit is part of the July 2021-launched Australian R&D tax incentive (R&DTI) program. The 43.5% tax credit initiative is available to pharmaceutical and biotechnology companies that make less than $20 million annually, offering them the chance to lower risk and speed up time to market for their assets. “[The incentive] allows us to manage our cash position quite efficiently compared to most other biotechs globally,” adds Latham.
Source: Pharmaceutical Technology
Merz makes a $185m bid for assets from bankrupt Acorda Source: Pharmaceutical Technology
Businesses that make over $20 million benefit from a slightly lower 38.5% tax credit with the remaining credit carried over to the following year. Suitable R&D activities are defined by the Income Tax Assessment Act 1997.
Free ReportHow is the Biopharmaceutical industry evolving?
2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects.
Benchmark the impact of major themes on the Biopharmaceutical industry.
Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
Evaluate the effects of COVID-19 on the sector. Download the full report to understand what to expect and how to align your strategies for success.
Source: Pharmaceutical Technology
Antigua & Barbuda (+1268)
Bosnia Herzegovina (+387)
Cape Verde Islands (+238)
Central African Republic (+236)
Dominican Republic (+1809)
Sao Tome & Principe (+239)
Trinidad & Tobago (+1868)
Turks & Caicos Islands (+1649)
United Arab Emirates (+971)
Virgin Islands - British (+1284)
Virgin Islands - US (+1340)
Bonaire, Sint Eustatius and Saba
British Indian Ocean Territory
French Southern Territories
Heard Island and McDonald Islands
Saint Helena, Ascension and Tristan da Cunha
Saint Pierre and Miquelon
Saint Vincent and The Grenadines
South Georgia and The South
US Minor Outlying Islands
-->By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Submit
Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Thank you.You will receive an email shortly. Please check for download the Report.